middle.news

ResMed Posts 9% Revenue Growth Amid Patent Battles and $150M Buyback

8:26am on Monday 3rd of November, 2025 AEDT Healthcare
Read Story

ResMed Posts 9% Revenue Growth Amid Patent Battles and $150M Buyback

8:26am on Monday 3rd of November, 2025 AEDT
Key Points
  • 9% year-over-year net revenue growth to $1.34 billion
  • 12% increase in net income to $348.5 million
  • Gross margin improved to 61.5% due to operational efficiencies
  • Recorded $15.8 million restructuring expenses related to workforce planning
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Resmed (ASX:RMD)
OPEN ARTICLE